INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,776,030 | +79.2% | 95,794 | +6.9% | 0.00% | +50.0% |
| Q2 2023 | $991,016 | -61.3% | 89,603 | -53.1% | 0.00% | -50.0% |
| Q1 2023 | $2,563,718 | +17.3% | 190,895 | +8.1% | 0.00% | 0.0% |
| Q4 2022 | $2,185,282 | +33.6% | 176,660 | +50.6% | 0.00% | +33.3% |
| Q3 2022 | $1,636,000 | +10.9% | 117,338 | +9.8% | 0.00% | +50.0% |
| Q2 2022 | $1,475,000 | -9.1% | 106,868 | +7.0% | 0.00% | 0.0% |
| Q1 2022 | $1,623,000 | +12.9% | 99,849 | +13.1% | 0.00% | 0.0% |
| Q4 2021 | $1,437,000 | – | 88,297 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |